comprehensive -WSS

comprehensive

author：fashion 2025-10-02 05:38:39 - browse：97

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Lilly’s obesity pill cuts 15% of weight at highest dose in mid

explore

WSS

Study finds new variant for Parkinson’s in African populations

Medical experts exlpore how to eliminate bias in clinical algorithms

GOP inquiry over gain

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Synthetic human embryos? Researchers say term is overblown

leisure time

comprehensive

leisure time

As demand for Covid shots wanes, Moderna seeks its next success

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

23andMe had bad news about my health. I wish a person had delivered it

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Walensky prepares to leave CDC — and Congress — behind

NYU Langone launches private ChatGPT for its health care data

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Brazil's Jair Bolsonaro is barred from running for office until 2030

Dobbs anniversary: the lost opportunity of abortion as health care

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

entertainment

Departing Stanford president retracts two papers

UnitedHealth wins $3.3 billion takeover of Amedisys

Psilocybin's anti

CDC advisory panel says seniors 'may' get RSV vaccine

2024 GOP presidential candidates spar over abortion in debate

Why more medical students aren't specializing in primary care

knowledge

explore

explore

focus